Chronic cerebrovascular insufficiency
A post-Soviet diagnostic category absent from international classifications. Used in the Russian-speaking region for patients with cognitive, emotional and vestibular symptoms attributed to chronic cerebral ischemia. Most cases correspond to vascular cognitive impairment or mixed dementia in DSM-5.
ICD-10 I67.84 drugs
Also known as: Chronic cerebral ischemia
Marketing claims without evidence base
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
- DPicamilon (nicotinoyl-GABA)Not recommended · Nootropics and vasoactive agents (local classification). Russian development.Picamilon (nicotinoyl-GABA) combines GABA with niacin and is prescribed and marketed to improve cerebral blood flow in chronic cerebrovascular insufficiency. No convincing benefit for this use has been shown – there is no solid evidence behind the claimed effect. What helps in chronic cerebrovascular insufficiency is managing risk factors: blood pressure, glucose, and lipid levels, plus quitting smoking. Discuss the specific plan with your doctor.
- DSemax (Met-Glu-His-Phe-Pro-Gly-Pro)Not recommended · Neuropeptides and nootropics (local classification). Russian development.Semax is a synthetic peptide (an ACTH fragment) given as nasal drops and marketed as a nootropic for chronic cerebrovascular insufficiency, memory, and attention. Convincing benefit for this use has not been shown: there is no solid evidence that it changes the course of chronic cerebrovascular disease. What actually helps in this condition is controlling risk factors – blood pressure, blood sugar, lipids, stopping smoking – together with antiplatelet therapy when a doctor prescribes it. Semax appears safe in this role, but it should not replace treatment with proven benefit, since that can mean missing the care you need.
- FMeldoniumNot recommended · Metabolic agents (local classification). Russian and Latvian development.Evidence tier F. The diagnostic category "chronic cerebrovascular insufficiency" used to justify meldonium prescribing in Russian outpatient care is absent from ICD-11 and from international neurology. Meldonium is not listed in any international vascular cognitive impairment or stroke prevention guideline. In patients with prior stroke or TIA, evidence-based secondary prevention is antiplatelet therapy (or anticoagulation for atrial fibrillation), high-intensity statin, blood pressure control to under 130/80 mmHg in most adults and diabetes management.
- FVinpocetineNot recommended · Psychostimulants and nootropics. Other psychostimulants and nootropicsEvidence tier F. The diagnostic entity "chronic cerebrovascular insufficiency" used to justify vinpocetine in Russian practice is absent from international classifications; international neurology uses vascular cognitive impairment and vascular dementia. The 2003 Cochrane review found no convincing efficacy. AAN, ESC and AHA guidelines do not list vinpocetine for cerebrovascular disease. The FDA 2019 safety communication added a pregnancy harm signal that further narrows any acceptable risk-benefit window.
How to read tiers A–F
Evidence tiers belong to the drug-indication pair, not to the drug as a whole: the same substance can be A for one condition and F for another.
- AStrong evidence – first or second line in international guidelines
- BRecommended in selected cases
- CStudy data contradict each other
- DBenefit not proven, no documented harm
- FDocumented harm, or risk without benefit